Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Last trade$7.12
Day change+$0.02 (+0.28%)
Day range$6.79 – $8.29
Volume598,812
Market cap$294M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$293.58M
Price / earnings
—
Price / book
1.17×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.05×
Profitability
Earnings per share
-$2.73
Return on assets
-40.63%
Return on equity
-44.98%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.52×
Quick ratio
8.52×
Cash ratio
2.32×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$91M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EVMN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Revenue
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
Selling, general and administrative
$8.78M
$8.48M
$6.64M
$9.31M
Research and development
$24.55M
$26.41M
$17.32M
$20.4M
Total operating expenses
$33.33M
$34.9M
$23.95M
$29.72M
Operating income
-$33.33M
-$34.9M
-$23.95M
-$29.72M
Interest expense
$0
$0
-$4K
$0
Income before taxes
-$30.88M
-$32.25M
-$21.67M
-$28.27M
Income taxes
$0
$0
$0
$0
Net income
-$30.88M
-$32.25M
-$21.67M
-$28.27M
Net income attributable to common shareholders
-$30.88M
-$32.25M
-$21.67M
-$28.27M
EBITDA
-$32.79M
-$34.34M
-$23.61M
-$29.39M
Basic earnings per share
-$0.85
-$0.89
-$0.64
-$1.42
Diluted earnings per share
-$0.85
-$0.89
-$0.64
-$1.42
Recent news
Company coverage with links to the original publishers.
Pelthos Therapeutics reported a Q3 loss of $3.09 per share, missing consensus estimates of $2.83 loss, and posted revenues of $15.4 million, falling 15.34% short of expectations. Despite the miss, the company showed improvement from a year-ago loss of $5.3 per share. The stock has declined 69.7% year-to-date while the S&P 500 gained 11.3%. Zacks assigned the stock a Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.
The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.